|
|
|||||||||||||||||||||||||||||||||||||||
  Durect Corp (DRRX) Durect is a biopharmaceutical company developing lifesaving investigational therapies derived from its Epigenetic Regulator Program. Larsucosterol, a chemical entity in clinical development, is the primary candidate in Co.'s Epigenetic Regulator Program. An orally bioavailable small molecule, larsucosterol has been shown in both in vitro and in vivo studies to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival. Co. is developing larsucosterol for alcohol-associated hepatitis, a life-threatening acute liver condition with no approved therapeutics. Co. has also investigated larsucosterol in patients with non-alcoholic steatohepatitis.
|
|
|||||||||||||||||||||||||||||||||||||||
Free DRRX Email Alerts:
Durect Corp (DRRX) Page | The Online Investor | www.TheOnlineInvestor.com | Copyright © 1998 - 2024, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.